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REVIEW

Cannabinoids for the Treatment of
Dermatologic Conditions
Torunn E. Sivesind1,6, Jalal Maghfour2,6, Hope Rietcheck1, Kevin Kamel3, Ali S. Malik4 and
Robert P. Dellavalle1,5
In recent years, cannabinoid (CB) products have
gained popularity among the public. The antiinflammatory properties of CBs have piqued the interest of researchers and clinicians because they
represent promising avenues for the treatment of
autoimmune and inflammatory skin disorders that may
be refractory to conventional therapy. The objective of
this study was to review the existing literature
regarding CBs for dermatologic conditions. A primary
literature search was conducted in October 2020, using
the PubMed and Embase databases, for all articles
published from 1965 to October 2020. Review articles,
studies using animal models, and nondermatologic
and pharmacologic studies were excluded. From 248
nonduplicated studies, 26 articles were included.
There were 13 articles on systemic CBs and 14 reports
on topical CBs. Selective CB receptor type 2 agonists
were found to be effective in treating diffuse cutaneous systemic sclerosis and dermatomyositis. Dronabinol showed efficacy for trichotillomania.
Sublingual cannabidiol and D-9-tetrahydrocannabinol
were successful in treating the pain associated with
epidermolysis bullosa. Available evidence suggests
that CBs may be effective for the treatment of various
inflammatory skin disorders. Although promising,
additional research is necessary to evaluate efficacy
and to determine dosing, safety, and long-term treatment guidelines.
JID Innovations (2022);2:100095 doi:10.1016/j.xjidi.2022.100095

INTRODUCTION
For many centuries, at least as early as BC 500, cannabis
has been widely used as an herbal medicine for the treatment of insomnia and gastrointestinal disorders, as an
anesthetic agent, and for religious practices (Zuardi, 2006).
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In the 19th century, investigation into the pharmacokinetics
of the active constituents of cannabis, the cannabinoids
(CBs), began to shed light on their potential application in
modern medicine (Zuardi, 2006). In recent years, there has
been an increase in both preclinical and clinical studies
exploring the use of CBs for the treatment of dermatologic
conditions (Eberlein et al., 2008; Ständer et al., 2006; Yuan
et al., 2014).
Given the increasing availability and popularity of CBcontaining skincare products and the increase in clinical
studies regarding the role of CBs in the treatment of dermatologic conditions, we aimed to review the existing evidence
on the use of CBs for the treatment of dermatologic conditions. To orient the reader, we first provide an overview of CB
classes, biological pathways, and mechanistic details as
follows.
CBs represent a diverse class of chemicals that share
structural and biologic similarities with the psychoactive
compound delta-9-tetrahydrocannabinol (D9-THC), which is
derived from Cannabis sativa (Eagleston et al., 2018).
There are three main classes of CBs: phytocannabinoids
(derived from the C. sativa plant), endocannabinoids
(endogenously produced in humans), and synthetic CBs
(synthesized in a laboratory) (Eagleston et al., 2018). An
introduction to representative CBs from each class, along
with their respective mechanisms, is provided in Table 1.
Phytocannabinoids include over 100 compounds; the most
notable of these are D9-THC and cannabidiol (CBD)
(Eagleston et al., 2018). The most clinically relevant endocannabinoids
are
anandamide
(AEA)
and
2arachidonoylglycerol (2-AG) (Eagleston et al., 2018),
whereas the endogenous fatty acid amide N-palmitoylethanolamide (N-PEA) is also recognized as an important
component of the endocannabinoid system (ECS), acting
through multiple pathways (Petrosino and Di Marzo, 2017).
Endocannabinoids have been shown to attenuate the production of proinflammatory cytokines and regulate
Abbreviations: D9-THC, delta-9-tetrahydrocannabinol; 2-AG, 2arachidonoylglycerol; ACR-CRISS, American College of Rheumatologycombined response index in diffuse cutaneous systemic sclerosis; AEA,
anandamide; CB, cannabinoid; CB1R, cannabinoid receptor 1; CB2R,
cannabinoid receptor 2; CBD, cannabidiol; CDASI, cutaneous dermatomyositis disease area and severity index; DM, dermatomyositis; ECS, endocannabinoid system; KC, keratinocyte; MRSS, modified Rodnan skin
thickness score; N-PEA, N-palmitoylethanolamide; QOLHEQ, Quality of Life
Hand Eczema Questionnaire; RCT, randomized controlled trial; SSc, systemic
sclerosis; VAS, Visual Analog Score
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CB Class

Mechanism of Action1

Selected Biologic Effects of
Interest

2-Arachidonylglycerol

Endocannabinoid (structure:
eicosanoid2)

Agonist of CB1R (primary location: CNS) and primary endogenous
agonist of CB2R (PNS and immune cells)3; additional affinity for GABAa,
TRPV1, PPAR-g, GPR55

Regulation of circulatory system;
emotion; cognition; pain; inflammation
(immune cells and neuroinflammation)

Anandamide (Narachidonoylethanolamine,
AEA)

Endocannabinoid (structure:
eicosanoid2)

Partial agonist of CB1R (primary location: CNS) and CB2R (primary
location: periphery)4; activator of TRPV1 cation channel2

Reward pathways; thermoregulation;
nociception

Phytocannabinoid (structure: classical
CB2)

Low affinity for CB1R/CB2R; can act as an antagonist of CB1R/CB2R
agonists and inverse agonist of multiple GPRs; 5-HT1a partial agonist at
low concentration (inverse agonist at higher concentrations); an
allosteric modulator of m and d opioid receptors; possible PPAR-g
agonist

Epilepsy; movement disorders;
inflammation; pain; anxiety

Dronabinol

Synthetic CB (structure: synthetic
analog of THC)

Agonist of CB1R and CB2R; complex CNS effects, including central
sympathomimetic action; possible agonism of CB1R receptors in
vomiting center of the medulla5; possible CB receptor‒mediated effects
in neural tissue; CB1R receptor agonism in hypothalamus stimulating
appetite5

Appetite; nausea/emesis; sleep apnea;
cannabis withdrawal

Nabilone

Synthetic CB (structure: synthetic
analog of D9-THC)

Agonist of CB1R and CB2R; possible agonism of CB1R receptors in
vomiting center of the medulla6

Chemotherapy-induced nausea/emesis;
neuropathic pain

N-PEA

Endocannabinoid-like (structure: fatty
acid amide)

Agonist of nuclear PPAR-a; agonist of GPR-55; indirect activator of
CB1R/CB2R and TRPV17

Pain (particularly neuropathic);
inflammation; mast cell degranulation

D9-THC

Phytocannabinoid (structure: classical
CB2)

Partial agonist of CB1R (action in CNS, PNS, and enteric nervous system)
and CB2R (PNS)

Neurological disorders; movement
disorders; pain; appetite; inflammation

Compound

CBD

Abbreviations: D9-THC, delta-9-tetrahydrocannabinol; 5-HT, 5-hydroxytryptamine; AEA, anandamide; CB, cannabinoid; CB1R, cannabinoid receptor 1; CB2R, cannabinoid receptor 2; CBD, cannabidiol;
GPR, G-protein-coupled receptor; N-PEA, N-palmitoylethanolamide; PNS, peripheral nervous system; PPAR-g, peroxisome proliferator‒activated receptor-g.
CB1R plays role in anxiety, pain, metabolism, addiction, inflammation; CB2R plays role in inflammation. GPR is a family of transmembrane receptors with signal transduction through cAMP or
phosphatidylinositol pathways. g-Aminobutyric acid (GABA)a plays a role in mood, sedation, memory, convulsion, and muscle tone. PPAR-g plays a role in inflammation.
Serotonin, (5HT1a) plays a role in mood, vascular tone, pain, emesis, and thermoregulation. TRPV1 plays a role in neuropathic pain.
1
Receptor types.
2
Console-Bram L, Marcu J, Abood ME. Cannabinoid receptors: nomenclature and pharmacological principles. Prog Neuropsychopharmacol Biol Psychiatry 2012;38:4‒15.
3
Baggelaar MP, Maccarrone M, van der Stelt M. 2-Arachidonoylglycerol: A signaling lipid with manifold actions in the brain. Prog Lipid Res 2018;71:1‒17.
4
Scherma M, Masia P, Satta V, Fratta W, Fadda P, Tanda G. Brain activity of anandamide: a rewarding bliss? Acta Pharmacol Sin 2019;40:309‒323.
5
Prescribers’ Digital Reference. Dronabinol mechanism of action. https://www.pdr.net/drug-summary/Marinol-dronabinol-2726#14 (accessed on September 2021).
6
Prescribers’ Digital Reference. Nabilone mechanism of action. https://www.pdr.net/drug-summary/Cesamet-nabilone-692#0 (accessed on September 2021).
7
Petrosino S, Di Marzo V. The pharmacology of palmitoylethanolamide and first data on the therapeutic efficacy of some of its new formulations Br J Pharmacol 2017;174:1349‒65.
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keratinocyte (KC) expression (Eagleston et al., 2018). Therefore, it is not surprising that malfunctioning of the ECS has
been implicated in a variety of pathologic skin conditions as
well as in cutaneous wounds.
Synthetic CBs, first produced in the 20th century, include
dronabinol and nabilone, which are approved by the United
States Food and Drug Administration for the treatment of
acquired immunodeficiency syndrome‒induced anorexia
and for chemotherapy-induced nausea and vomiting (Taylor
et al., 2020).
The physiologic effects of CBs are mediated through CB
receptor 1 (CB1R) and CB receptor 2 (CB2R), which are
members of the large family of G protein-coupled receptors.
Both CB1R and CB2R are expressed on cutaneous nerve fibers, mast cells, and KCs (Ständer et al., 2005). CB1Rs are the
predominant CB type in the CNS and appear at lower concentrations in the peripheral nervous system; in the enteric
nervous system; as well as in the heart, liver, and muscle
tissues (Nikan et al., 2016). CB2R is notable for its presence
in the immune system, with expression among cells of the
hematopoietic lineage and organs of the immune system,
such as the spleen and thymus (Basu et al., 2011).
With regard to binding effects, CB1Rs are primarily
responsible for memory, mood, and modulation of pain
sensation through the release of neurotransmitters (Nikan
et al., 2016). It is thought that CB2Rs are largely responsible for the anti-inflammatory and immunomodulatory effects of CBs (Nikan et al., 2016). CB2R stimulation in KCs has
been shown to promote the release of analgesic opioid
peptides, which can modulate pain at a local level as well as
systemically (through the CNS) (Caterina, 2014).
CBs can interact with transient receptor potential channels,
also known as ionotropic CB receptors, which have been
shown to modulate pain and itch perception (Caterina,
2014). Transient receptor potential channels are abundant
on cutaneous peripheral neurons.
SKIN HEALTH AND THE ECS
The ECS is an integral component of skin homeostasis,
comprising CB1R and CB2R, the endogenous CBs 2-AG
and AEA, lipid mediators such as N-PEA, and hydrolytic
enzymes such as fatty acid amide hydrolase (Eagleston
et al., 2018). N-PEA itself has a low binding affinity for
CB1Rs and CB2Rs but is able to activate CB receptors
indirectly and enhance the effects of endogenous CB
compounds such as AEA. N-PEA serves as an alternative
substrate to fatty acid amide hydrolase; this in turn potentiates the physiologic effects of AEA. This is known as
the entourage effect (Ho et al., 2008). Downstream
signaling mediated by AEA leads to the activation of
peroxisome proliferator‒activated receptor-a. The signaling
response is characterized by the inhibition of proinflammatory cytokines, including IL-2; the induction, proliferation, and differentiation of KCs; and increased
synthesis of lipids, including fatty acids and ceramides,
which play an important role in maintaining skin barrier
function and integrity (Kreitzer and Stella, 2009).
Transcription factors such as NF-kB are essential to the
pathogenesis of inflammatory skin disorders; NF-kB has been
shown to activate downstream molecular signaling pathway,

resulting in the upregulation of proinflammatory mediators
such as IL-8, matrix metalloproteinase, and VEGF (Hoesel
and Schmid, 2013). Results of an in vitro model of human
KC cell lines show that CBD is able to inhibit NF-kB transcription and subsequently inactivate the inflammatory
cascade (Motwani et al., 2018).
MECHANISTIC ACTION OF TOPICAL CBS
Topical D9-THC and CBD have been shown to suppress the
levels of proinflammatory cytokines, including IL such as IL-6
and IL-17, whereas pretreatment with CBD has resulted in an
upregulation of IL-10, an anti-inflammatory cytokine (Kozela
et al., 2013). These immune-modulating effects appear to be
mediated independently of CB signaling pathways.
MECHANISTIC ACTION OF ORAL CBS
Recent studies have illustrated several mechanisms through
which oral CBs exert their effects. For example, systemic
sclerosis (SSc) fibroblasts are known to possess increased
numbers of CB2R, through which oral CB2R agonists act to
reduce TGFb and collagen production and limit the fibrosis
characteristic of SSc (Spiera et al., 2020). Modulation of the
ECS system by CB2R agonists stimulates the resolution of
innate immune responses by activating the production of
proresolving lipid mediators, such as lipoxin-A4 and B4 and
resolvin-D1 and D3. Activation of CB2Rs present in
lymphoid tissue has been shown to inhibit cytokine release
from immune cells and, therefore, decrease inflammation
(Spiera et al., 2020). The marked anti-inflammatory action of
CB2R agonists is due in part to inhibition of leukotriene B4, a
neutrophil chemoattractant, and allows for effective clearance of inflammatory stimuli by inhibiting antiphagocytic
prostanoids, including prostaglandin E2, thromboxane B2,
and prostaglandin F2a (Motwani et al., 2018).
Oral CB2R agonists have also been shown to modulate the
immune system in patients with dermatomyositis (DM). A
recent study showed a reduction in the production of proinflammatory cytokines, including TNF-a, IFN-a, and IFN-b,
among those treated with ajulemic acid/lenabasum, a CB2R
agonist (Robinson et al., 2017).
A summary figure illustrating the mechanistic actions and
therapeutic effects of CBs as they relate to skin health and the
immune system is provided in Figure 1.
A systematic review was conducted, adhering to the
Preferred Reporting Items for Systematic Reviews and MetaAnalyses guidelines (Liberati et al., 2009) as illustrated in
Figure 2. A search in the Embase and PubMed databases for
all peer-reviewed articles in the English language was performed in October 2020, using the following search terms:
dermatology, dermatologic conditions, cutaneous, skin,
psoriasis, pruritus, and oral, topical, cannabinoids.
The resulting articles were screened on the basis of eligibility criteria. Only articles written in English and discussing
the study of CB-based products in humans for treating skin
conditions were included. Review articles, studies regarding
pharmacology, and in vitro or in vivo studies were excluded.
Study design and outcome data were extracted from each
included article and are summarized in Tables 2 and 3.
The search criteria identified 270 published articles from
1965 to October 2020. After duplicates were removed, two
www.jidinnovations.org
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(-)

CB2R
Selective
Agonist

PEA

CBD

CB1R

CB2R

Keratinocyte
NF-κB transcription

Upregulation of
IL-8, MMP-9, VEGF
(inflammatory cascade)

eCB effects
enhanced

Release of analgesic
opioid peptides

PPAR-α
activation

3. Pruritus and Pain:
- Release of analgesic opioid peptides
following stimulation of CB2R exerts effects
locally and systemically.
- Cannabinoids have direct effects at
cutaneous peripheral neurons TRP channels
which modulate pain and itch perception.

2. Maintaining Skin Barrier Function/Integrity:

1. Immune Regulation:
CB2R Agonists:
- Stimulation of innate immune
response via activation of
pro-resolving lipid mediators.
- Decreased inflammation via
inhibition of pro-inflammatory
cytokines (TNF-α, IFN-B), LTB4 and
antiphagocytic prostanoids (PGE2,
TXB2, PGF2a).
- Limited fibrosis via reduction of
TGF-band collagen production.

CBD/THC:
- Inactivation of inflammatory
cascade via inhibition of NF-κB
transcription.
- Suppression of IL-6, IL-17, and
upregulation of IL-10 independent of
CBR signaling pathways.

PEA:
- Lipid amides decrease mast cell
activation and histamine release.
- Entourage effect results in
enhancement of endogenous
cannabinoid inhibition of IL-2.

- Induction, proliferation, and differentiation of
keratinocytes.
- Increased synthesis of lipids.
- CBD exerts antioxidant effects, combating
oxidative tissue damage.

Oral Agents: (Drops, Inhaled, Sublingual)
- Selective CB2 Receptor Agonists
- Dronabinol
- THC
- CBD

Topical Agents:
- CBD
- PEA
- THC
- combination CBD‒THC oil

Therapeutic Effects:
- Decreased pruritus, pain, photosensitivity
- Decreased skin thickness in sclerotic skin
- Improved sleep, fatigue, and functional activity
- Improvement in hair pulling scale

Therapeutic Effects:
- Improved skin dryness, pruritus, erythema

Treatment of:
- Diffuse Cutaneous Systemic Sclerosis
- Dermatomyositis
- Trichotillomania
- Epidermolysis Bullosa
- Recalcitrant pruritus

- Resolution of scaling and plaque formation
- Wound closure/healing, reduction in blisters
- Pain relief
Treatment of:
- Dermatitis (Atopic, Asteatotic, and Seborrheic)
- Psoriasis Vulgaris
- Chronic pruritus
- Calciphylaxis (nonuremic)
- Epidermolysis Bullosa

Figure 1. Cannabinoid mechanisms of action. Proposed mechanisms of action of cannabinoids on the immune and cutaneous neuroendocrine system. CB,
cannabinoid; CBR, cannabinoid receptor; CB1R, cannabinoid receptor 1; CB2R, cannabinoid receptor 2; CBD, cannabidiol; MMP-9, matrix metalloproteinase
9; PG, prostaglandin; THC, tetrahydrocannabinol; TRP, transient receptor potential; TXB2, thromboxane B2.

reviewers (TES and JM) independently screened articles on
the basis of title, abstract, and full-text review to determine
eligibility. One article (Maghfour et al., 2020) known to the
authors from previous research was also included, with 26
reports eligible for inclusion in this review. Of these, 12
were clinical trials (randomized, open label); six were
cohort studies, including one retrospective study; six were
case reports or case series; and two were pilot studies.
Retrieved articles included assessments of both topical and
oral CBs.
4
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There were 13 reports that assessed the effects of systemic
CBs (oral, inhalation, or sublingual preparations), of which
seven were clinical trials; there were two pilot studies, two
case series, one case report, and one experimental study (see
Table 2).
There were 13 articles assessing the utility of topical CBs
(shown in Table 3). Of these, four were randomized
controlled trials (RCTs), five were cohort studies, and four
were case reports or case series. Only one article investigated
the effects of both topical and oral CBs.

TE Sivesind et al.

Identification
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Records identified through
database searching
(n = 270)

Additional records identified
through other sources
(n = 1)

Figure 2. PRISMA flow diagram. The
search process is depicted using a flow
diagram adapted from the PRISMA
guidelines. PRISMA, Preferred
Reporting Items for Systematic
Reviews and Meta-Analyses.

Included

Eligibility

Screening

Records after duplicates removed
(n = 248)

Records screened
(n = 248)

Full-text articles assessed
for eligibility
(n = 48)

Records excluded
(n = 200)

Full-text articles excluded, with
reasons
in vitro/in vivo studies (n = 4)
Incomplete data (n = 1)
Irrelevant or non-clinical outcome
measures (n = 4)
Commentary/opinion (n = 3)
Duplicate studies (n = 10)

Studies included in
qualitative synthesis
(n = 26)

EFFICACY OF ORAL CBS
Diffuse cutaneous SSc

Current dermatologic literature regarding the use of oral CBs
is focused on the treatment of diffuse cutaneous systemic
sclerosis. The strongest evidence of safety and efficacy is
derived from two RCTs and three open-label extension trials—in these trials, selective CB2R agonists (ajulemic acid;
trade name lenabasum, formerly anabasum) were
investigated.
Lenabasum is a nonpsychoactive synthetic CB that is a
CB2R agonist. Its therapeutic effects occur through the
modulation of the immune system and resolution of fibrosis,
through two putative molecular mechanisms (Burstein,
2021). After CB2R and phospholipase A2 activation, free
arachidonic acid enters one of two pathways: the cyclooxygenase-2e or lipoxygenase-mediated pathway (Burstein,
2021). The cyclooxygenase-2 pathway facilitates caspase
production and ultimately apoptosis and resolution of
chronic inflammation, whereas the lipoxygenase pathway
produces lipoxin A4 and other proresolving mediators
(Burstein, 2021).
Lenabasum was investigated for the treatment of SSc in 42
participants on immunosuppressive therapy, who received
either placebo or oral lenabasum for a total duration of 84
days (Spiera et al., 2017: “A phase 2 study.”). After
discontinuation of therapy or placebo, all participants were
followed from days 85 to 113. Therapeutic dosage was based
on randomization and consisted of the following: 5 mg
lenabasum daily, 20 mg lenabasum daily, or 20 mg

lenabasum twice a day for days 1 to 28, followed by 20 mg
twice daily on days 29 to 84, or placebo on days 1 to 84. In
the overall disease assessment, the treated group experienced
a greater improvement than the placebo group (American
College of Rheumatology-combined response index in
diffuse cutaneous systemic sclerosis [ACR-CRISS] score: 33
vs. 1% at week 16 in the lenabasum and placebo groups,
respectively, P ¼ 0.044). There was also a greater reduction
in skin thickness and pruritus observed in the lenabasum
group. In an open-label extension (Spiera et al. 2017: “Safety
and efficacy.”), all participants received lenabasum for a
median duration of 194 days, and at 10 weeks, modified
Rodnan skin thickness score (MRSS) decreased by 3.2
compared with that at the baseline (P ¼ 0.0001).
In a double-blind placebo-controlled RCT (Spiera et al.,
2020), the safety and efficacy of oral Lenabasum were
explored in 42 subjects (aged 18e69 years) with diffuse
cutaneous SSc. This included 32 female participants (9 in the
placebo group and 23 in the treatment group). During the
initial 4 weeks, participants in the treated group received one
of the following: 5 mg or 20 mg of lenabasum once daily. For
the remaining treatment period (8 weeks), all subjects in the
lenabasum-treated group received a dose of 20 mg twice
daily. The control group (n ¼ 12) received placebo
throughout the entire study duration (n ¼ 12 weeks). All
participants were assessed at weeks 4, 8, 12, and 16.
All participants, including the control group, were
receiving background immunosuppressive medications
(mycophenolate, etanercept, or hydroxychloroquine). All
www.jidinnovations.org
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Study Design,
Number of
Participants

Spiera et al. 2017

1

RCT, n ¼ 42

Spiera et al. 2017

2

Spiera et al. 2018

Condition, Source

Cannabinoid Treatment
Regimen

Results

Adverse Events

Oral lenabasum 5 mg or 20 mg
q.d. or 20 mg b.i.d. for 4 wks,
then 20 mg b.i.d. for 8 wks; or
PBO .

Significant Improvement in ACR-CRISS scores,
(including MRSS, PtGA, and PGA) compared
with those of the PBO (over 16 wks), P ¼ 0.044.

n ¼ 5 (14%), mild fatigue; n ¼ 4 (11%), mild/
moderate URI; dizziness occurred in two (6%)
subjects.

OLE, n ¼ 36

Oral lenabasum (20 mg b.i.d.)

Skin induration improved; no withdrawals due
to medication

AEs: 10% subjects had mild fatigue (14%) and
mild/moderate URI (11% of subjects); dizziness
in 6%.

2

OLE, n ¼ 19

Oral lenabasum (20 mg b.i.d.)

Improvements from study start were ACR-CRISS
score ¼ 0.33, MRSS ¼ -8.6 (1.5), HAQ-DI ¼ ‒
0.14 (0.11), PGA ¼ ‒0.9 (0.5), and 5-D itch ¼ ‒
2.3 (0.8). FVC% predicted was stable from study
start.

One subject had a life-threatening AE, 3 (8%)
had severe AEs, 21 (58%) moderate, and 8
(22%) mild AEs. Seven (19%) had AEs related to
lenabasum; AEs include URI, UTI, diarrhea, and
skin ulcers.

Spiera et al. 2019

2

OLE, n ¼ 36

Oral lenabasum (20 mg b.i.d.),
assessed at 4 weeks, then every
8 weeks

Compared with the study start, ACR-CRISS
median score: 0.99 (0.43 IQR) at wk 76 and
MRSS declined by mean (SD) ¼ ‒10.7 (7.2)
points. FVC% predicted decreased by 2.5%
from the study start.

At week 92, 97% of subjects had at least 1 AE. 7
(19%) had at least 1 AE considered (fatigue),
which was related to lenabasum

Spiera et al. 2020

1

RCT, n ¼ 42

Oral lenabasum, dose 5 mg or
20 mg once a day, or 20 mg
b.i.d. for 4 weeks, then 20 mg
b.i.d. for 8 weeks, or PBO

Median ACR-CRISS score at wk 16 was 0.33
versus 0.00 in PBO. PtGA treatment differences:
1.2 (0.67) (P ¼ 0.04, P ¼ 0.08 at wk 16). SSPRO
treatment effect (SE) ¼ ‒16 (6.0) (P ¼ 0.005, P ¼
0.01 at wk 12); 5-D itch was ‒1.8 (1.0) (P ¼
0.04, P ¼ 0.08 at wk 12). HAQ-DI at 12 weeks:
‒0.32 (0.12) (P ¼ 0.006, P ¼ 0.01).

Lenabasum versus PBO: AEs 63% versus 60%.
In lenabasum group, dizziness and nausea were
most common. No evidence of toxicity.

Nogueira et al. 2019

5

Case report, n ¼ 1

Inhaled cannabis (30 g/day)

Improvement in all symptoms and total
resolution of Raynaud’s phenomenon and
dyspnea.

No AEs reported

Cocchiara et al. 2019

3

Cohort study, n ¼ 25

CBD (10%) orally b.i.d. and
topical application.

Significant reduction in pain VAS and HAQ-DI
at 2 months.

No AEs reported

Werth et al. 2018

1

RCT, n ¼ 22

Oral lenabasum in escalating
doses for12 weeks.

Mean reduction in CDASI activity by 5 points
at all visits after 4 weeks (P ¼ 0.02); Greater
improvement than PBO in PROM of global skin
disease and overall disease assessments, skin
symptoms1 (P  0.1) at visits after wk 4.

No AEs reported

Werth et al. 2019

2

OLE, n ¼ 22

Oral lenabasum (20 mg b.i.d.)

At week 28, decrease in CDASI score by 15
points. Physician overall disease VAS ¼ ‒2.6
(1.90) points, 82.3% of subjects achieving at
least 1 point and 20% improvement. Significant
improvement in Skindex 29.

1 mild AEs in five subjects (25%)
Two subjects (10%) experienced DM flare

3

Pilot study, n ¼ 14

Oral dronabinol (2.5‒15 mg/
day)

MGH-HPS scores decreased from a mean of
16.5  4.4 at baseline to 8.7  5.5 at study
endpoint (mean effective dose ¼ 11.1  4);
NIMH-Trichotillomania severity: 11.21
decreased to 4.36 (P < 0.001)

No AEs reported

Diffuse cutaneous SSc

Dermatomyositis (skin predominant)

Trichotillomania
Grant et al. 2011
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Abbreviations: ACR-CRISS, American College of Rheumatology-Combined Response Index in diffuse cutaneous Systemic Sclerosis; AE, adverse event; b.i.d., twice a day; CBD, cannabidiol; CDASI, Cutaneous
Dermatomyositis Disease Area and Severity Index; DM, dermatomyositis; EB, epidermolysis bullosa; HAQ-DI, Health Assessment Questionnaire-Disability Index; IQR, interquartile range; MGH-HPS,
Massachusetts General Hospital Hair Pulling Scale; MRSS, Modified Rodnan Skin thickness Score; NIMH, National Institute of Mental Health; OLE, open label extension; PBO, placebo; PGA, Physician Global
Assessment; PROM, patient reported outcome measure; ptGA, patient Global-Assessment; q.d., every day; RCT, randomized controlled trial; SSc, systemic sclerosis; SSPRO, Scleroderma Skin Patient-Reported
Outcome; THC, D9-tetrahydrocannabinol; URI, upper respiratory infection; UTI, urinary tract infection; VAS, Visual Analog Score.
1
Skin symptoms included: pain interfering with activities, fatigue, photosensitivity and itch.

AEs not reported
HU210 (through a skin patch or
microdialysis)
3
Dvorak et al. 2003

Pilot study, n ¼ 12

Resolution of pruritus. Skin blood flow and
neurogenic-mediated flare responses were
reduced (P < 0.003 and P < 0.03)

Disturbance in coordination, resolved with a
decrease in dronabinol (by 2.5 mg)
Resolution of pruritus in three of three patients
after 4‒6 hs of dronabinol dose
5 mg Dronabinol nightly
Case series, n ¼ 3
4
Neff et al. 2002

Pruritus (various causes)

4
Schräder et al. 2019

Epidermolysis bullosa

Condition, Source

Table 2. Continued

Level of
Evidence

Study Design,
Number of
Participants

Case Series, n ¼ 3

Cannabinoid Treatment
Regimen

Sublingual THC/CBD (20 mg/
mg, CBD; 13 mg/mg,THC)

Results

Improved pain control and decreased pruritus
with CBD/THC oil. VAS reduction from 9/10 to
3/10 at 1 month for one subject; 40% reduction
in pain reported in one subject; VAS reduction
from 9/10 to 1‒4/10 at 1 month in one subject.

Adverse Events

Increased appetite (n ¼ 1), drug‒drug
interaction with opioid in one patient (reduced
reaction time, altered sense of time)

Cannabinoids in Dermatology

treated subjects experienced an overall improvement as
assessed by the ACR-CRISS score. The ACR-CRISS is a validated outcome measure for SSc. It is composed of five core
sets of measures, including MRSS, percent predicted forced
vital capacity, the health assessment questionnaire disability
index, and the patient and clinical global assessments. A
score of 0.6 or higher indicates the likelihood that a patient
improved with treatment (Khanna et al., 2016). At week 16,
the ACR-CRISS score for the treated group was 0.33 (interquartile range: 0.01e0.82), compared with 0.00 (interquartile range: 0.000e0.16) in the placebo group (P ¼ 0.04).
Participants also experienced improvement in the following
domains: scleroderma skin patient-reported outcome (P <
0.005), MRSS (mean  SEM: 2.6  1.9 at week 16, P <
0.05), and 5-D itch score (mean  SEM: 1.8  1.0 at week
12, P ¼ 0.04).
Two open-label trials (Spiera et al., 2018, 2019) further
explored the safety and efficacy of oral lenabasum among
participants who had completed the phase II trial. A total of
25 subjects remained on lenabasum for 52 weeks, with
additional improvement in ACR-CRISS score (56%)
compared with that at the baseline (before therapy initiation)
(Spiera et al., 2017: “Safety and efficacy.”). A reduction in
skin thickness (MRSS ¼ 8.6) and decrease in pruritus (5-D
itch scale ¼ 2.3) were also observed. In another openlabel study (Spiera et al., 2019), participants who remained
on lenabasum for >18 months continued to experience
clinical improvement in ACR-CRISS score (0.99) and skin
thickness reduction (MRSS ¼ 10.2).
It is important to note that although lenabasum appeared to
show great promise for the treatment of scleroderma, on the
basis of the results of phase II trials and open-label extension
studies, it has failed phase III testing, owing to its inability to
meet the primary efficacy endpoint of significant ACR-CRISS
improvement compared with placebo (Terry, 2020). Notably,
ACR-CRISS was the primary outcome measure in the successful phase II trial of lenabasum. However, posthoc analysis of the phase III data showed that participants who
received background immunosuppression and were treated
with 20 mg lenabasum twice daily had a smaller decline in
forced vital capacity at 1 year than those who were treated
with placebo (nominal P ¼ 0.048). Treatment with lenabasum was also associated with a greater likelihood of a stable
forced vital capacity percentage predicted (64% lenabasum
vs. 35% placebo).
Both inhaled cannabis and oral formulations of CBD oil
have resulted in improvement in the symptoms of SSc. In a
study (Cocchiara et al., 2019) on subjects with SSc (n ¼ 25;
22 female) that assessed both oral ingestion of 10% CBD oil
(five drops twice daily) and local application of CBD oil to
cutaneous ulcers, there was a significant improvement in
pain, Visual Analog Score (VAS) improved from 94.8 at
baseline to 40.9 after treatment (P < 0.0001), and the health
assessment questionnaire disability index decreased from 1.1
to 0.46 after a 2-month course of therapy.
In a previous study (Nogueira et al., 2019), a patient with
SSc who smoked 30 g of C. sativa daily experienced an
improvement in dyspnea, Raynaud’s phenomenon, and pain.
However, there were no specific metrics measured in this
study.
www.jidinnovations.org
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Table 3. Summary of Studies Investigating Topical Cannabinoids
Level of
Evidence

Study Design

Atopic dermatitis
Yuan et al. 2014

1

RCT, n ¼ 60

Palmieri et al. 2019

3

Retrospective cohort, n ¼ 5

Eberlein et al. 2008

3

Cohort, n ¼ 2,456

Pulvirenti et al. 2007

3

Cohort study, n ¼ 20

Maghfour et al. 2020)

3

Cohort study, n ¼ 16

Pruritus (various causes)
Szepietowski et al. 2005

3

OLE, n ¼ 21

Visse et al. 2017

3

Cohort, n¼ 100

Ständer et al. 2006

3

Observational, n ¼ 7

Topical N-PEA, daily,
2 wks for 6 months

Prurigo nodularis
Ständer et al. 2006

3

Observational, n ¼ 13

Topical N-PEA, daily Reduction in pruritus in nine
for 7.6 wks
subjects

AEs not reported

Lichen simplex chronicus
Ständer et al. 2006

3

Observational, n ¼ 2

Topical N-PEA,
daily for 3
wks

(VAS: 8.5 vs. 0; P < 0.05) in
both Pts

AEs not reported

Psoriasis vulgaris
Friedman et al. 2020

5

Case report, n ¼ 1

Lesion clearance after 2 wks.
At 2 months, Pt started using
product as maintenance
therapy (once a wks)

AEs not reported

Palmieri et al. 2019

3

Retrospective cohort, n ¼ 5

THC soap infused
with hemp 5 mg/mL,
hair oil with THC
distillate dissolved oil
5 mg/mL
Topical CBD
ointment, b.i.d. for 3
months

A decrease in the number of
psoriasis plaques. Improved
PASI at day 90 (P < 0.001).

AEs not reported

Scalp psoriasis and
seborrheic dermatitis
Vincenzi et al. 2020

3

Observational study, n ¼ 50

0.075% CBD in
shampoo, daily

Reduction in arborizing
vessel/twisted capillary
inflammation and scaling by
day 14 in both scalp psoriasis
and seborrheic dermatitis.

AEs not reported

Epidermolysis bullosa
Chelliah et al. 2018

4

Case Series, n ¼ 3

Topical CBD, daily

Condition, Source

Cannabinoid
Treatment Regimen

Results

Adverse Events

AEs not reported
Reduction in skin scaling,
dryness, and itching
(P < 0.05)
AEs not reported
Topical CBD, twice
Hydration increased (P <
daily, for 3 months 0.01); TEWL improved (P <
0.001); improvement in
SCORAD index score
Pruritus, burning, and
Topical N-PEA, b.i.d.
Significant reduction in
erythema
for 6 wks
dryness, excoriations,
lichenification, scaling,
erythema, and pruritus
(P < 0.001).
AEs not reported
Topical adelmidrol
16 (80%) experienced
complete resolution of AD
symptoms
AEs not reported
Topical CBD, b.i.d. for Reduction in POEM: (16 
2 wks
1.35) to (8.25  1.80), P <
0.0007. QOLHEQ from a
mean score of 20.9  2.06 to
8.375  1.609 (P < 0.004)
Topical N-PEA/AEA

Topical AEA/N-PEA

Reduction in xerosis in 80%
of Pts; decrease in pruritus
(P < 0.001); n ¼ 8
experienced resolution of itch
Topical N-PEA, twice Pruritus VAS decreased after
daily, for 2 wks
2-wk treatment (P < 0.001).

Improvement in pruritus,
unspecified. No changes in
the intensity of pruritus due to
aquagenic and/or cholestasis

AEs not reported

12 subjects
experienced the
following AEs:
pruritus, stinging,
scaling, and
erythema)
AEs not reported

Decreased pain, faster AEs not reported
wound healing
(continued )
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Table 3. Continued
Condition, Source

Level of
Evidence

Wounds (pyoderma gangrenosum,
calciphylaxis)
Maida and Corban 2017
4

Maida et al. 2020

2

Study Design

Cannabinoid
Treatment Regimen

Results

Adverse Events

Case series, n ¼ 3, Pyoderma
Gangrenosum

THC 7 mg/ml þ CBD Daily pain score decreased (P Onset of analgesia 3‒
5 min after
9 mg/ml). Route: 0.5- <0.05) (n ¼ 2). All cases had
pain reduction of 30% or application of topical
1mL to wound bed.
CBD/THC
greater. Average daily opioid
dose was reduced
Multicohort open-label trial, n ¼ Topical THC and CBD Wound closure in up to 90%
AEs not reported
33, calciphylaxis
of cases in nonuremic Pts.

Abbreviations: AD, atopic dermatitis; AE, adverse event; AEA, anandamide; b.i.d., twice a day; CBD, cannabidiol; N-PEA, N-palmitoylethanolamide; PG,
pyoderma gangrenosum; Pt, Patient; sig, significant; POEM, patient-oriented eczema measure; QOLHEQ, Quality of Life Hand Eczema Questionnaire; RCT,
randomized controlled trial; SCORAD, scoring atopic dermatitis; TEWL, transepidermal water loss; THC, tetrahydrocannabinol; VAS, Visual Analog Score.

DM

Epidermolysis bullosa

The role of lenabasum was investigated in a study of 22
participants with DM: 11 subjects received 20 mg oral
lenabasum twice daily, whereas the remaining half of participants were in the placebo group for a total duration of 16
weeks (Werth et al., 2018). Compared with placebo, a fivepoint reduction in cutaneous disease activity severity index
score (CDASI) was observed at 16 weeks (P < 0.05). Patientreported metrics of global skin disease, including photosensitivity and itch, were significantly improved at week 4.
Treated participants also experienced an improvement in
fatigue, sleep, and functional activity.
Of the 22 participants in the study, 20 were eligible for an
open-label extension (Spiera et al., 2019, 2017; Werth
et al., 2019), in which all subjects received oral lenabasum for 28 weeks. A 15.4-point reduction in CDASI, a
reduction in VAS results for itch and pain, and QOL
improvement measured through Skindex-29 were noted after treatment completion. There were two serious adverse
events reported (fatigue and metastatic prostate cancer),
which were considered unrelated to lenabasum; no serious
events related to lenabasum were reported, and no subjects
discontinued the open-label extension owing to adverse
events related to the drug (Spiera et al., 2019). With regard
to DM, lenabasum also failed to meet its primary endpoint
in phase III: total improvement score at week 28. Of note,
regulatory mandates prompted the change from CDASI to
total improvement score as the primary outcome for the
phase III trial, whereas the validated CDASI scale was
downgraded to a secondary endpoint. Nonetheless, posthoc
analysis of phase III data revealed that participants with skin
predominant DM (minimal muscle activity) experienced a
significant improvement in CDASI score (P ¼ 0.016) (Global
Newswire, 2021).

Phytocannabinoids (D9-THC and CBD) were explored as a
therapeutic option among three patients with epidermolysis
bullosa (aged 3661 years) (Schräder et al., 2019). Sublingual delivery of D9-THC (13 mg/ml) and CBD (20 mg/ml) was
provided to all participants. The main outcome measured
was an improvement in pain and pruritus; improvement was
noted after only 1 month of treatment.
In one patient, after 2 years of treatment with the sublingual CB regimen, the addition of topically applied D9THCCBD oil (1 mg CBD with 0.65 mg D9-THC) enabled
the cessation of topical morphine and amitriptyline; the
patient also continued on the sublingual CB regimen. A
patient with recessive dystrophic epidermolysis bullosa
(generalized severe) continued to experience severe pain
despite being on a regimen of multiple opioids; after 1
week of sublingual CBDD9-THC combination oil, the
patient reported a 40% reduction in pain (Schräder et al.,
2019).

Trichotillomania

Histamine-induced pruritus

The effect of oral dronabinol was investigated in 14 female
patients (mean age ¼ 33.3 years) with trichotillomania for a
period of 12 weeks (Grant et al., 2011). The mean effective
dose of dronabinol was 11.6 mg (range: 2.515 mg). At the
end of the study, there was an improvement in the Massachusetts General Hospital Hair Pulling Scale from 16.5  4.4
at baseline to 8.7  5.5 (P ¼ 0.001).

In an experimental study (Dvorak et al., 2003), pruritus was
induced in 18 participants and was successfully treated with
peripheral administration (dermal patch) of HU210, a CB2R
agonist. Skin blood flow and neurogenic-mediated flare responses were the major outcome measures; both were
reduced from baseline (P < 0.003 and P < 0.03,
respectively).

Pruritus secondary to systemic diseases

In this review, one report (Neff et al., 2002) assessed the
efficacy of oral D9-THC for the treatment of recalcitrant
pruritus secondary to cholestatic liver disease. All three
patients in the report were unresponsive to doxepin,
naltrexone, cholestyramine, UV therapy, and plasmapheresis; they experienced severe and debilitating pruritus that
resulted in impaired QOL, depression, and suicidal ideation. Patients were started on 5 mg of D9-THC at bedtime
and experienced a decrease in pruritus, along with improvements in sleep and functional activities, with treatment
effects lasting from 4 to 6 hours. One patient developed
disturbance in coordination, which improved after a dose
reduction to 2.5 mg at night (Neff et al., 2002).

www.jidinnovations.org
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EFFICACY OF TOPICAL CBS
The effectiveness of topical CBD, N-PEA, and D9-THC was
reported for the following conditions: chronic and uremic
pruritus, postinflammatory scars, ulcers secondary to pyoderma gangrenosum and calciphylaxis (uremic and nonuremic types), epidermolysis bullosa, psoriasis vulgaris, and
dermatitis (atopic, asteatotic, and seborrheic).
Atopic dermatitis

The efficacy of topical CBs for dermatitis treatment was reported six times (Cocchiara et al., 2019; Eberlein et al., 2008;
Maghfour et al., 2020; Palmieri et al., 2019; Pulvirenti et al.,
2007; Yuan et al., 2014). A total of 60 female participants
with asteatotic eczema experienced an improvement in
scaling, dryness, and itch (P < 0.05) after the use of topical
N-PEA and AEA (Yuan et al., 2014). Similar findings were
reported among 21 subjects (Maghfour et al., 2020; Palmieri
et al., 2019) with atopic dermatitis when treated with a 1%
CBD infusion gel and ointment. There was an improvement
in transepidermal water loss (P < 0.001) and PASI score (P <
0.001) after a treatment period of 3 months (Palmieri et al.,
2019) and in the patient-oriented eczema measure score
from 16 to 8.1 (P < 0.007) (Maghfour et al., 2020) at 2 weeks.
In the same study (Maghfour et al., 2020) in which authors
assessed the emotional burden of atopic dermatitis using the
Quality of Life Hand Eczema Questionnaire (QOLHEQ), a
significant reduction in the emotional domain of the QOLHEQ was noted after treatment completion (20.9  2.06 vs.
8.37  1.609, P < 0.004)
Topical adelmidrol, an analog of N-PEA, appeared effective for the treatment of pediatric atopic dermatitis (Pulvirenti
et al., 2007). After a treatment course of 4 weeks, all participants experienced a significant improvement in pruritus
and erythema; 16 (80%) experienced clinical resolution.
Eberlein et al. (2008) assessed the efficacy of topical N-PEA
in a large dataset of 2,456 patients (aged 21.2  17.8 years;
65% female). Participants from various geographic locations
received topical N-PEA with a mean treatment duration of 38
days. All subjects experienced symptom improvement of at
least 70% in the following domains: dryness, excoriation,
lichenification, scaling, erythema, and pruritus (P < 0.01).
Psoriasis vulgaris

Six patients with psoriasis (Friedman et al., 2020; Palmieri
et al., 2019) were treated with topical CBD (n ¼ 5) or D9THC (n ¼ 1). All patients had a resolution of psoriasis plaques. Patients treated with topical CBD had an overall
improvement in PASI score on day 90 (P < 0.001).
Scalp psoriasis and seborrheic dermatitis

Vincenzi et al. (2020) investigated CBD oil (0.075%) as a
treatment for scalp psoriasis (n ¼ 22) and scalp seborrheic
dermatitis (n ¼ 28). Efficacy was assessed using trichoscopy
at baseline and on day 14. There was a reduction in arborizing vessel/twisted capillary inflammation and scaling by
day 14 (2.3 vs. 0.5, P < 0.001). Symptoms of itching and
burning were also reduced from 6.9 to 1.3 for scalp psoriasis
and from 4.5 to 1.0 for seborrheic dermatitis (both with P <
0.0001).
10
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Calciphylaxis

In a multicohort open-label trial (Maida et al., 2020), 32
participants with calciphylaxis, not caused by uremia,
received topical CBD (3.75 mg/ml) and minimal D9-THC (<1
mg per day), which was applied to wound beds and periwound tissues. Wound closure was achieved in 90% of cases
after 1 year of treatment. There was only one patient in the
trial with uremic calciphylaxis located on the bilateral lower
legs; this patient experienced an increase in granulation tissue (58% on the left and 78% on the right leg wound) with an
overall reduction in wound size by 9% on the left and 5% on
the right. No localized or systemic effects were reported;
however, the patient expired owing to coexisting heart
disease.
Pyoderma gangrenosum

Topical combined CBDeD9-THC appears to be effective for
pain relief in patients with pyoderma gangrenosum. Three
patients achieved symptomatic relief of pain (P < 0.05), with
an overall pain reduction of 30% (Maida and Corban, 2017).
Idiopathic pruritus

Topical N-PEA solution was assessed as a therapy for chronic
pruritus secondary to xerosis in 100 participants (mean age ¼
56 years; range ¼ 18e83 years; 56 female subjects) (Visse
et al., 2017). After 2 weeks of twice-daily use, there was a
significant improvement in VAS-measured pruritus (P <
0.001). However, in both the treated and control groups, 13
individuals reported worsening of pruritus, stinging, scaling,
and erythema.
Pruritus secondary to systemic disease

Uremic pruritus secondary to renal disease can be debilitating and often represents a therapeutic challenge. In a trial
conducted by Szepietowski et al. (2005), 21 subjects were
instructed to apply topical N-PEA/AEA cream twice a day.
After a 3-week course of treatment, there was a significant
reduction in pruritus (P < 0.0001); eight subjects (38.1%) had
complete resolution of pruritus (Szepietowski et al., 2005).
Topical N-PEA was also explored for pruritus secondary to
the following conditions: cholestasis due to hepatitis C (n ¼
1), pruritus due to limited scleroderma (CREST [calcinosis,
Raynaud phenomenon, esophageal dysmotility, sclerodactyly, and telangiectasia] syndrome) (n ¼ 1), and aquagenic pruritus (n ¼ 2) (Stӓnder et al., 2006). Subjects were
instructed to apply the N-PEA test product on a daily basis,
with treatment ranging from 2 weeks to 6 months. No
improvement was noted among patients with cholestasis or
aquagenic pruritus.
Prurigo nodularis and lichen simplex chronicus

Prurigo nodularis and lichen simplex are chronic skin conditions in which pruritus is the hallmark symptom. In a study
on these conditions (Stӓnder et al., 2006), topical N-PEA was
used for an average of 7.6 weeks among participants with
prurigo nodularis (n ¼ 13, VAS: 6.6 for baseline vs. 3.3 after
treatment). However, four (30.7%) subjects were unresponsive to topical N-PEA. Two patients with lichen simplex
chronicus were instructed to apply topical N-PEA for a 3week course; subjects achieved a significant improvement
in pruritus (VAS ¼ 8.5 at baseline, VAS ¼ 0 at end of treatment) (Stӓnder et al., 2006).
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Epidermolysis bullosa

Topical CBD was investigated in two reports (Chelliah et al.,
2018; Eberlein et al., 2008) with six pediatric patients (aged 6
months to 10 years). All patients experienced a reduction in
blisters by at least 50%, with improved wound healing and
decreased use of opioid analgesics.
ADVERSE EFFECTS OF TOPICAL CBS
Topical CBs have shown a significantly lower side effect
profile than oral CBs. For topical CBs, adverse events were
reported in nine subjects receiving topical N-PEA who
experienced at least one of the following: stinging, erythema,
and/or burning after application.
ADVERSE EFFECTS OF ORAL CBS
All patients treated with lenabasum experienced at least one
adverse event, including mild fatigue, dizziness, and upper
respiratory tract infection. DM flare was reported in two
participants. One patient experienced a disturbance in coordination after administration of oral 5 mg dronabinol,
which resolved with a 50% dose reduction.
This systematic review sought to examine the present use
of CB-based products in dermatology. Analysis of the
included research revealed that the application of CBs has
been studied for 13 different dermatologic conditions, with
systemic sclerosis and DM investigated most extensively.
Current evidence highlights the use of topical CBs in the
treatment of pruritus, reduction of erythema, and enhanced
wound healing. These clinical effects rely on CBs ability to
inhibit the production of proinflammatory cytokines and
modulate the immune system.
Findings from the available published data, although
relatively scarce, highlight the promising results of CBs for
the treatment of various dermatologic conditions. Despite
the expanding body of evidence relating to the applicability
and efficacy of CBs, there continue to be significant knowledge gaps. This review confirmed that existing evidence
from high-quality studies (particularly RCTs) remains
limited. Further clinical studies pertaining to the therapeutic
dosage and long-term safety of both topical and oral CBs are
highly warranted. Physicians who prescribe CBs should be
aware of the systemic effects reported in the literature and
bear in mind that long-term safety data exist primarily for the
selective CB2R agonists only.
In addition, clinical trials investigating autoimmune skin
conditions such as scleroderma and DM should be mindful of
the necessity for ongoing immunosuppression in potential
study participants and ethical implications related to the fact
that systemic disease negates the possibility of a placebo-only
group. Such trials should be designed with an eye toward
including outcomes that allow for tapering of prednisone and
the inclusion of participants who are on stable background
doses of immunosuppressive medications.
LIMITATIONS
A significant limitation of our review is the small number
of RCTs available for inclusion, resulting in a greater proportion of lower-level evidence obtained from case reports
or case series. Selection bias may also have affected this

review because positive outcomes are more likely to be
published.
In conclusion, both oral and topical CBs appear to be
promising therapies for the treatment of various inflammatory
and autoimmune skin disorders. Despite limited studies, the
compilation of current evidence from the published literature
supports the utility of topical and systemic CBs for the
treatment of primary inflammatory skin disorders such as
DM, diffuse cutaneous systemic sclerosis, atopic dermatitis,
leg ulcers, and epidermolysis bullosa. In addition, thoughtfully designed RCTs are warranted to provide the necessary
evidence base to support the use of CBs for the treatment of
these dermatologic conditions. Studies should aim to control
for confounders that may affect outcomes, such as the use of
ongoing immunosuppressive agents and the potential anxiolytic properties of CBs, which could influence patientreported outcomes. The minimal side effect profiles associated with CBs, particularly with topicals, are an important
attribute and further encourage additional studies to support
the application of CBs in dermatology practice.
ORCIDs
Torunn E. Sivesind: http://orcid.org/0000-0003-4805-0632
Jalal Maghfour: http://orcid.org/0000-0002-1121-2709
Hope Rietcheck: http://orcid.org/0000-0002-4724-9570
Kevin Kamel: http://orcid.org/0000-0001-7284-0584
Ali S. Malik: http://orcid.org/0000-0002-5828-2974
Robert P. Dellavalle: http://orcid.org/0000-0001-8132-088X

AUTHOR CONTRIBUTIONS
Conceptualization: TES, RPD; Data Curation: TES, JM, HR; Investigation: TES,
JM, HR; Methodology: TES, JM, HR; Supervision: RPD; Validation: TES, JM,
HR; Writing - Original Draft Preparation: TES, JM; Writing - Review and
Editing: TES, JM, KK, ASM, RPD

CONFLICT OF INTEREST
RPD is editor in chief of the Journal of Medical Internet Research (JMIR)
Dermatology, a joint coordinating editor for Cochrane Skin, a dermatology
section editor for UpToDate, a social media editor for the Journal of the
American Academy of Dermatology, and a podcast editor for the Journal of
Investigative Dermatology. He is a coordinating editor representative on
Cochrane Council. TES is an editorial board member-at-large for JMIR
Dermatology. The remaining authors state no conflict of interest.

ACKNOWLEDGMENTS
RPD receives editorial stipends (American Academy of Dermatology and
Journal of Investigative Dermatology), royalties (UpToDate), and expense
reimbursement from Cochrane Skin. TES, United States receives fellowship
funding (Pfizer Global Medical Grant [58858477] Dermatology Fellowship
2020, principal investigator: RPD) and fees for serving as a medical advisor
and investigator for Antedotum. The remaining authors have no disclosures to
report. No funding was received for this work.

REFERENCES
Basu S, Ray A, Dittel BN. Cannabinoid receptor 2 is critical for the homing
and retention of marginal zone B lineage cells and for efficient T-independent immune responses. J Immunol 2011;187:5720e32.
Burstein S. Molecular mechanisms for the inflammation-resolving actions of
Lenabasum. Mol Pharmacol 2021;99:125e32.
Caterina MJ. TRP channel cannabinoid receptors in skin sensation, homeostasis, and inflammation. ACS Chem Neurosci 2014;5:1107e16.
Chelliah MP, Zinn Z, Khuu P, Teng JMC. Self-initiated use of topical cannabidiol oil for epidermolysis bullosa. Pediatr Dermatol 2018;35:e224e7.
Cocchiara E, Spinella A, Magnani L, Lumetti F, Palermo A, Balocchi G, et al.
AB0645 cannabinoids in the treatment of pain related to systemic sclerosis
skin ulcers: our experience [abstract]. Ann Rheum Dis 2019;78:1784.
Dvorak M, Watkinson A, McGlone F, Rukwied R. Histamine induced responses are attenuated by a cannabinoid receptor agonist in human skin.

www.jidinnovations.org

11

TE Sivesind et al.

Cannabinoids in Dermatology
Inflamm Res Off J Eur Histamine Res Soc Al. Inflamm Res 2003;52:
238e45.
Eagleston LRM, Kalani NK, Patel RR, Flaten HK, Dunnick CA, Dellavalle RP.
Cannabinoids in dermatology: a scoping review. Dermatol Online J 2018;24.
Eberlein B, Eicke C, Reinhardt HW, Ring J. Adjuvant treatment of atopic
eczema: assessment of an emollient containing N-palmitoylethanolamine
(ATOPA study). J Eur Acad Dermatol Venereol 2008;22:73e82.
Friedman AJ, Momeni K, Kogan M. Topical cannabinoids for the management
of psoriasis vulgaris: report of a case and review of the literature. J Drugs
Dermatol 2020;19:795.
Global newswire. Corbus pharmaceuticals announces topline results from
DETERMINE phase 3 study of Lenabasum for treatment of dermatomyositis.
https://www.globenewswire.com/en/news-release/2021/06/24/2252567/0/en/
Corbus-Pharmaceuticals-Announces-Topline-Results-from-DETERMINEPhase-3-Study-of-Lenabasum-for-Treatment-of-Dermatomyositis.html;
(accessed September 2021).
Grant JE, Odlaug BL, Chamberlain SR, Kim SW. Dronabinol, a cannabinoid
agonist, reduces hair pulling in trichotillomania: a pilot study. Psychopharmacol (Berlin) 2011;218:493e502.
Ho WS, Barrett DA, Randall MD. ‘Entourage’ effects of N -palmitoylethanolamide and N -oleoylethanolamide on vasorelaxation to anandamide occur
through TRPV1 receptors. Br J Pharmacol 2008;155:837e46.
Hoesel B, Schmid JA. The complexity of NF-kB signaling in inflammation and
cancer. Mol Cancer 2013;12:86.
Khanna D, Berrocal VJ, Giannini EH, Seibold JR, Merkel PA, Mayes MD, et al.
The American College of Rheumatology provisional composite response
index for clinical trials in early diffuse cutaneous systemic sclerosis.
Arthritis Rheumatol 2016;68:299e311.
Kozela E, Juknat A, Kaushansky N, Rimmerman N, Ben-Nun A, Vogel Z.
Cannabinoids decrease the th17 inflammatory autoimmune phenotype.
J Neuroimmune Pharmacol 2013;8:1265e76.
Kreitzer FR, Stella N. The therapeutic potential of novel cannabinoid receptors. Pharmacol Ther 2009;122:83e96.
Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA,
et al. The PRISMA statement for reporting systematic reviews and metaanalyses of studies that evaluate healthcare interventions: explanation
and elaboration. BMJ 2009;339:b2700.
Maghfour J, Rietcheck HR, Rundle CW, Runion TM, Jafri ZA, Dercon S, et al.
An observational study of the application of a topical cannabinoid gel on
sensitive dry skin. J Drugs Dermatol 2020;19:1204e8.
Maida V, Corban J. Topical medical cannabis: A new treatment for wound pain-three
cases of pyoderma gangrenosum. J Pain Symptom Manage 2017;54:732e6.
Maida V, Shi RB, Fazzari FGT, Zomparelli L. Promoting wound healing of
uremic calciphylaxis leg ulcers using topical cannabis-based medicines.
Dermatol Ther 2020;33:e14419.
Motwani MP, Bennett F, Norris PC, Maini AA, George MJ, Newson J, et al.
Potent anti-inflammatory and pro-resolving effects of Anabasum in a human model of self-resolving acute inflammation. Clin Pharmacol Ther
2018;104:675e86.
Neff GW, O’Brien CB, Reddy KR, Bergasa NV, Regev A, Molina E, et al. Preliminary observation with dronabinol in patients with intractable pruritus
secondary to cholestatic liver disease. Am J Gastroenterol 2002;97:2117e9.
Nikan M, Nabavi SM, Manayi A. Ligands for cannabinoid receptors, promising anticancer agents. Life Sci 2016;146:124e30.
Nogueira AR, Shoenfeld Y, Amital H. Cannabis sativa as a Potential Treatment
for Systemic Sclerosis. Isr Med Assoc J 2019;21:217e8.
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